1. Home
  2. ZLAB
  3. ZLAB News

Latest Zai Lab Limited (ZLAB) News on June 1, 2025

ZLAB

Newsfile

2 days ago

Sienna Resources Inc. Announces Private Placement

ZLAB

Energy Global

2 days ago

European Energy completes sale of Polish wind portfolio to Enea Group

ZLAB

Newsfile

2 days ago

Max Resource Corp. Announces Participation in THE Mining Investment Event, Quebec City, June 3-5, 2025

ZLAB

Newsfile

2 days ago

Carbone Restaurant Group is a GOLD Sponsor at the Centurion One Capital 6th Annual LA Summit

First Foundation Bank review (2025): Personal and business banking with competitive online rates
ZLAB

Yahoo Personal Finance

2 days ago

First Foundation Bank review (2025): Personal and business banking with competitive online rates

ZLAB

Investing.com

2 days ago

Airbnb shares dip as Truist cuts stock to Sell on weak summer trends, valuation

Report: Slower economy doesn't dim downtown Austin's dynamism
ZLAB

Austin American-Statesman

2 days ago

Report: Slower economy doesn't dim downtown Austin's dynamism

Nvidia (NVDA) Gets Wall Street Boost on Strong Q1 Results and Upbeat Guidance
ZLAB

GuruFocus.com

2 days ago

Nvidia (NVDA) Gets Wall Street Boost on Strong Q1 Results and Upbeat Guidance

Zai Lab Announces Participation in Investor Conferences in June 2025
ZLAB

Business Wire

2 days ago

Zai Lab Announces Participation in Investor Conferences in June 2025

Exploring 3 High Growth Tech Stocks In The US Market
ZLAB

Simply Wall St.

13 days ago

Exploring 3 High Growth Tech Stocks In The US Market

ZLAB

MT Newswires

13 days ago

Sector Update: Health Care Stocks Steady-to-Lower Pre-Bell Monday

ZLAB

MT Newswires

13 days ago

Zai Lab Receives US FDA Fast-Track Designation for Potential Small Cell Lung Cancer Treatment

Zai Lab Receives U.S. FDA Fast Track Designation for ZL-1310, a DLL3-Targeted Antibody-Drug Conjugate, for Treatment of Extensive-Stage Small Cell Lung Cancer
ZLAB

Business Wire

13 days ago

Zai Lab Receives U.S. FDA Fast Track Designation for ZL-1310, a DLL3-Targeted Antibody-Drug Conjugate, for Treatment of Extensive-Stage Small Cell Lung Cancer

ZLAB

MT Newswires

17 days ago

Zai Lab Insider Sold Shares Worth $2,731,507, According to a Recent SEC Filing

Zai Lab First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag
ZLAB

Simply Wall St.

22 days ago

Zai Lab First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag

Zai Lab Ltd (ZLAB) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ...
ZLAB

GuruFocus.com

23 days ago

Zai Lab Ltd (ZLAB) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ...

Zai Lab Limited (ZLAB) Reports Q1 Earnings: What Key Metrics Have to Say
ZLAB

Zacks

24 days ago

Zai Lab Limited (ZLAB) Reports Q1 Earnings: What Key Metrics Have to Say

ZLAB

MT Newswires

24 days ago

Zai Lab's Q1 Loss Narrows, Revenue Rises; 2025 Revenue Guidance Reiterated

Zai Lab Announces First Quarter 2025 Financial Results and Recent Corporate Updates
ZLAB

Business Wire

24 days ago

Zai Lab Announces First Quarter 2025 Financial Results and Recent Corporate Updates

Zai Lab Limited (ZLAB): Among the Best Breakout Stocks to Buy According to Analysts
ZLAB

Insider Monkey

a month ago

Zai Lab Limited (ZLAB): Among the Best Breakout Stocks to Buy According to Analysts

Zai Lab Presents Data Highlighting Potential of Internally Developed, Next-Generation Oncology Therapies at AACR 2025
ZLAB

Business Wire

a month ago

Zai Lab Presents Data Highlighting Potential of Internally Developed, Next-Generation Oncology Therapies at AACR 2025

Zai Lab to Present Data from Phase 1 Trial of DLL3-Targeted Antibody-Drug Conjugate (ADC) ZL-1310 at 2025 ASCO Annual Meeting
ZLAB

Business Wire

a month ago

Zai Lab to Present Data from Phase 1 Trial of DLL3-Targeted Antibody-Drug Conjugate (ADC) ZL-1310 at 2025 ASCO Annual Meeting

ZLAB

MT Newswires

a month ago

Zai Lab's Cancer Drug Application Accepted by Chinese Regulator

Zai Lab Announces Acceptance of Supplemental New Drug Application for Repotrectinib for Patients with NTRK-Positive Solid Tumors
ZLAB

Business Wire

a month ago

Zai Lab Announces Acceptance of Supplemental New Drug Application for Repotrectinib for Patients with NTRK-Positive Solid Tumors

All You Need to Know About Zai Lab Limited (ZLAB) Rating Upgrade to Buy
ZLAB

Zacks

2 months ago

All You Need to Know About Zai Lab Limited (ZLAB) Rating Upgrade to Buy

Zai Lab Limited (ZLAB) Moves 21.5% Higher: Will This Strength Last?
ZLAB

Zacks

2 months ago

Zai Lab Limited (ZLAB) Moves 21.5% Higher: Will This Strength Last?

Zai Lab to Announce First Quarter 2025 Financial Results and Recent Corporate Updates on May 8, 2025
ZLAB

Business Wire

2 months ago

Zai Lab to Announce First Quarter 2025 Financial Results and Recent Corporate Updates on May 8, 2025

Zai Lab Limited (ZLAB): Among Stocks Insiders Sold in April After Trump’s Tariff Rollout
ZLAB

Insider Monkey

2 months ago

Zai Lab Limited (ZLAB): Among Stocks Insiders Sold in April After Trump’s Tariff Rollout

ZLAB

Argus Research

2 months ago

Daily – Vickers Top Buyers & Sellers for 04/04/2025

Spotlight On High Growth Tech Stocks In The US March 2025
ZLAB

Simply Wall St.

2 months ago

Spotlight On High Growth Tech Stocks In The US March 2025

Zai Lab to Present New Data from Internally Developed, Next-Generation Oncology Candidates at AACR 2025 Annual Meeting
ZLAB

Business Wire

2 months ago

Zai Lab to Present New Data from Internally Developed, Next-Generation Oncology Candidates at AACR 2025 Annual Meeting

Is Zai Lab Limited (ZLAB) the Best Performing Growth Stock in 2025?
ZLAB

Insider Monkey

3 months ago

Is Zai Lab Limited (ZLAB) the Best Performing Growth Stock in 2025?

Zai Lab announces acceptance of BLA for TIVDAK in cervical cancer
ZLAB

TipRanks

3 months ago

Zai Lab announces acceptance of BLA for TIVDAK in cervical cancer

ZLAB

MT Newswires

3 months ago

JPMorgan Adjusts Price Target on Zai Lab to $51 From $44, Keeps Overweight Rating

ZLAB

MT Newswires

3 months ago

Zai Lab's Tivdak Marketing Application Accepted in China for Cervical Cancer Treatment

Zai Lab Announces Acceptance of Biologics License Application for TIVDAK for the Treatment of Patients with Recurrent or Metastatic Cervical Cancer
ZLAB

Business Wire

3 months ago

Zai Lab Announces Acceptance of Biologics License Application for TIVDAK for the Treatment of Patients with Recurrent or Metastatic Cervical Cancer

Wall Street Analysts Think Zai Lab Limited (ZLAB) Could Surge 64.42%: Read This Before Placing a Bet
ZLAB

Zacks

3 months ago

Wall Street Analysts Think Zai Lab Limited (ZLAB) Could Surge 64.42%: Read This Before Placing a Bet

ZLAB

MT Newswires

3 months ago

Zai Lab Shares Fall After BofA Securities Downgrade

ZLAB

MT Newswires

3 months ago

BofA Securities Downgrades Zai Lab to Neutral

Zai Lab Announces Participation in Investor Conferences in March 2025
ZLAB

Business Wire

3 months ago

Zai Lab Announces Participation in Investor Conferences in March 2025

Zai Lab Limited (NASDAQ:ZLAB) Just Released Its Annual Results And Analysts Are Updating Their Estimates
ZLAB

Simply Wall St.

3 months ago

Zai Lab Limited (NASDAQ:ZLAB) Just Released Its Annual Results And Analysts Are Updating Their Estimates

Zai Lab Full Year 2024 Earnings: Beats Expectations
ZLAB

Simply Wall St.

3 months ago

Zai Lab Full Year 2024 Earnings: Beats Expectations

Zai Lab Ltd (ZLAB) Q4 2024 Earnings Call Highlights: Robust Revenue Growth and Path to Profitability
ZLAB

GuruFocus.com

3 months ago

Zai Lab Ltd (ZLAB) Q4 2024 Earnings Call Highlights: Robust Revenue Growth and Path to Profitability

China Biotech's Sales Jump 66% But Bottom Line Misses Views
ZLAB

Investor's Business Daily

3 months ago

China Biotech's Sales Jump 66% But Bottom Line Misses Views

ZLAB

MT Newswires

3 months ago

Zai Lab's Q4 Loss Narrows, Revenue Rises; 2025 Revenue Guidance Set

Zai Lab Announces Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Updates
ZLAB

Business Wire

3 months ago

Zai Lab Announces Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Updates

Is Zai Lab Limited (ZLAB) the Best Performing Mid Cap Stock to Buy According to Analysts?
ZLAB

Insider Monkey

3 months ago

Is Zai Lab Limited (ZLAB) the Best Performing Mid Cap Stock to Buy According to Analysts?

Zai Lab Limited (ZLAB) Surges 9.0%: Is This an Indication of Further Gains?
ZLAB

Zacks

3 months ago

Zai Lab Limited (ZLAB) Surges 9.0%: Is This an Indication of Further Gains?

High Growth Tech Stocks To Watch In February 2025
ZLAB

Simply Wall St.

3 months ago

High Growth Tech Stocks To Watch In February 2025

With 73% ownership in Zai Lab Limited (NASDAQ:ZLAB), institutional investors have a lot riding on the business
ZLAB

Simply Wall St.

3 months ago

With 73% ownership in Zai Lab Limited (NASDAQ:ZLAB), institutional investors have a lot riding on the business

Wall Street Analysts Believe Zai Lab Limited (ZLAB) Could Rally 95.6%: Here's is How to Trade
ZLAB

Zacks

4 months ago

Wall Street Analysts Believe Zai Lab Limited (ZLAB) Could Rally 95.6%: Here's is How to Trade

Zai Lab to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide Recent Corporate Updates on February 27, 2025
ZLAB

Business Wire

4 months ago

Zai Lab to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide Recent Corporate Updates on February 27, 2025

FDA grants ODD status to Zai Lab’s lung cancer treatment
ZLAB

Pharmaceutical Technology

4 months ago

FDA grants ODD status to Zai Lab’s lung cancer treatment

ZLAB

MT Newswires

4 months ago

Zai Lab Says FDA Grants Orphan Drug Designation for ZL-1310

Why Is Andreas Halvorsen Bullish On Zai Lab Limited (ZLAB) Now?
ZLAB

Insider Monkey

4 months ago

Why Is Andreas Halvorsen Bullish On Zai Lab Limited (ZLAB) Now?

Zai Lab Receives Orphan Drug Designation from the U.S. FDA for ZL-1310 (DLL3 ADC) for the Treatment of Small Cell Lung Cancer (SCLC)
ZLAB

Business Wire

4 months ago

Zai Lab Receives Orphan Drug Designation from the U.S. FDA for ZL-1310 (DLL3 ADC) for the Treatment of Small Cell Lung Cancer (SCLC)

High Growth Tech Stocks To Explore In January 2025
ZLAB

Simply Wall St.

4 months ago

High Growth Tech Stocks To Explore In January 2025

Here’s Why Analysts Are Bullish on Zai Lab Limited (ZLAB)
ZLAB

Insider Monkey

4 months ago

Here’s Why Analysts Are Bullish on Zai Lab Limited (ZLAB)

Market Sentiment Around Loss-Making Zai Lab Limited (NASDAQ:ZLAB)
ZLAB

Simply Wall St.

4 months ago

Market Sentiment Around Loss-Making Zai Lab Limited (NASDAQ:ZLAB)

ZLAB

MT Newswires

4 months ago

Sector Update: Health Care Stocks Softer Friday Afternoon

ZLAB

MT Newswires

4 months ago

Zai Lab's Schizophrenia Drug Application Accepted by Chinese Regulator; Shares Rise

Zai Lab Announces Acceptance of New Drug Application for KarXT for the Treatment of Schizophrenia
ZLAB

Business Wire

4 months ago

Zai Lab Announces Acceptance of New Drug Application for KarXT for the Treatment of Schizophrenia

Zai Labs announces positive results in China arm of Phase III cervical cancer trial
ZLAB

Clinical Trials Arena

5 months ago

Zai Labs announces positive results in China arm of Phase III cervical cancer trial

ZLAB

MT Newswires

5 months ago

Zai Lab Reports Improved Overall Survival in Phase 3 Trial of Tivdak in Cervical Cancer Patients

Zai Lab Announces Positive Topline Results for TIVDAK in the China Subpopulation of the Global Phase 3 innovaTV 301 Trial in Patients with Recurrent or Metastatic Cervical Cancer
ZLAB

Business Wire

5 months ago

Zai Lab Announces Positive Topline Results for TIVDAK in the China Subpopulation of the Global Phase 3 innovaTV 301 Trial in Patients with Recurrent or Metastatic Cervical Cancer

Sage Therapeutics (SAGE) Moves 35.1% Higher: Will This Strength Last?
ZLAB

Zacks

5 months ago

Sage Therapeutics (SAGE) Moves 35.1% Higher: Will This Strength Last?

Zai Lab, Vertex Pharmaceuticals announce povetacicept license agreement
ZLAB

TipRanks

5 months ago

Zai Lab, Vertex Pharmaceuticals announce povetacicept license agreement

ZLAB

MT Newswires

5 months ago

Vertex, Zai Lab Partner Over Povetacicept Development in China, 4 Other Regions

Vertex and Zai Lab Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan Region and Singapore
ZLAB

Business Wire

5 months ago

Vertex and Zai Lab Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan Region and Singapore

Zai Lab and Vertex Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan region and Singapore
ZLAB

Business Wire

5 months ago

Zai Lab and Vertex Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan region and Singapore

ZLAB

MT Newswires

5 months ago

Zai Lab Licenses MediLink Therapeutics' Antibody-Drug Conjugate Platform

Zai Lab Announces Strategic Partnership with MediLink Therapeutics to Develop a Novel LRRC15 Antibody-Drug Conjugate
ZLAB

Business Wire

5 months ago

Zai Lab Announces Strategic Partnership with MediLink Therapeutics to Develop a Novel LRRC15 Antibody-Drug Conjugate

Zai Lab Limited (ZLAB) Upgraded to Buy: What Does It Mean for the Stock?
ZLAB

Zacks

5 months ago

Zai Lab Limited (ZLAB) Upgraded to Buy: What Does It Mean for the Stock?

Zai Lab (NASDAQ:ZLAB) shareholders have endured a 59% loss from investing in the stock three years ago
ZLAB

Simply Wall St.

5 months ago

Zai Lab (NASDAQ:ZLAB) shareholders have endured a 59% loss from investing in the stock three years ago

Zai Lab Announces Participation in Investor Conference in January 2025
ZLAB

Business Wire

6 months ago

Zai Lab Announces Participation in Investor Conference in January 2025

Zai Lab, Novocure announce PANOVA-3 trial met primary endpoint
ZLAB

TipRanks

6 months ago

Zai Lab, Novocure announce PANOVA-3 trial met primary endpoint

ZLAB

MT Newswires

6 months ago

Update: NovoCure's Shares Rise as Pancreatic Cancer Trial Meets Primary Endpoint

NovoCure's Tumor-Treating Electric Fields Shows Promise In Pancreatic Cancer Patients
ZLAB

Benzinga

6 months ago

NovoCure's Tumor-Treating Electric Fields Shows Promise In Pancreatic Cancer Patients

ZLAB

MT Newswires

6 months ago

Zai Lab, NovoCure Say Pancreatic Cancer Trial Meets Primary Endpoint

Zai Lab and Novocure Announce Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer
ZLAB

Business Wire

6 months ago

Zai Lab and Novocure Announce Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer

Zai Lab Announces the Inclusion of AUGTYRO® (repotrectinib) for ROS1+ NSCLC and Other Updates in China’s National Reimbursement Drug List
ZLAB

Business Wire

6 months ago

Zai Lab Announces the Inclusion of AUGTYRO® (repotrectinib) for ROS1+ NSCLC and Other Updates in China’s National Reimbursement Drug List

Exploring Three High Growth Tech Stocks in the United States
ZLAB

Simply Wall St.

6 months ago

Exploring Three High Growth Tech Stocks in the United States

Zai Lab and Pfizer to commercialise XACDURO in China
ZLAB

Pharmaceutical Technology

6 months ago

Zai Lab and Pfizer to commercialise XACDURO in China

ZLAB

MT Newswires

6 months ago

Zai Lab, Pfizer Collaborate for Marketing Antibacterial Drug in China

Zai Lab and Pfizer Announce Strategic Collaboration on the Novel Antibacterial Drug XACDURO® (Sulbactam-Durlobactam)
ZLAB

Business Wire

6 months ago

Zai Lab and Pfizer Announce Strategic Collaboration on the Novel Antibacterial Drug XACDURO® (Sulbactam-Durlobactam)

Zai Lab Announces Anticipated Closing of Public Offering of American Depositary Shares and Full Exercise of Underwriters' Option to Purchase Additional American Depositary Shares
ZLAB

Business Wire

6 months ago

Zai Lab Announces Anticipated Closing of Public Offering of American Depositary Shares and Full Exercise of Underwriters' Option to Purchase Additional American Depositary Shares

Analyst Estimates: Here's What Brokers Think Of Zai Lab Limited (NASDAQ:ZLAB) After Its Third-Quarter Report
ZLAB

Simply Wall St.

7 months ago

Analyst Estimates: Here's What Brokers Think Of Zai Lab Limited (NASDAQ:ZLAB) After Its Third-Quarter Report

ZLAB

MT Newswires

7 months ago

Zai Lab Prices $200 Million Public Offering

Zai Lab Announces Pricing of Public Offering of American Depositary Shares
ZLAB

Business Wire

7 months ago

Zai Lab Announces Pricing of Public Offering of American Depositary Shares

Zai Lab Third Quarter 2024 Earnings: EPS Beats Expectations
ZLAB

Simply Wall St.

7 months ago

Zai Lab Third Quarter 2024 Earnings: EPS Beats Expectations

ZLAB

MT Newswires

7 months ago

Zai Lab Launches $200 Million ADS Offering; Stock Falls After-Hours

Zai Lab Announces Proposed Public Offering of American Depositary Shares
ZLAB

Business Wire

7 months ago

Zai Lab Announces Proposed Public Offering of American Depositary Shares

Zai Lab Ltd (ZLAB) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Path to Profitability
ZLAB

GuruFocus.com

7 months ago

Zai Lab Ltd (ZLAB) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Path to Profitability

Compared to Estimates, Zai Lab Limited (ZLAB) Q3 Earnings: A Look at Key Metrics
ZLAB

Zacks

7 months ago

Compared to Estimates, Zai Lab Limited (ZLAB) Q3 Earnings: A Look at Key Metrics

Zai Lab and argenx announce NMPA approval for sBLA for VYVGART Hytrulo
ZLAB

Pharmaceutical Technology

7 months ago

Zai Lab and argenx announce NMPA approval for sBLA for VYVGART Hytrulo

ZLAB

MT Newswires

7 months ago

Zai Lab's Q3 Loss Narrows, Revenue Rises

Zai Lab Announces Third Quarter 2024 Financial Results and Recent Corporate Updates
ZLAB

Business Wire

7 months ago

Zai Lab Announces Third Quarter 2024 Financial Results and Recent Corporate Updates

ZLAB

MT Newswires

7 months ago

Zai Lab, Argenx Receive Chinese Approval for Neuromuscular Drug Vyvgart Hytrulo

Zai Lab and argenx Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China
ZLAB

Business Wire

7 months ago

Zai Lab and argenx Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China

Zai Lab presents positive outcomes from KarXT Phase III trial for schizophrenia
ZLAB

Clinical Trials Arena

7 months ago

Zai Lab presents positive outcomes from KarXT Phase III trial for schizophrenia

Share on Social Networks: